

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Hu CD45 BUV395 HI30 100Tst

RRID:AB_2869519

Type: Antibody

Proper Citation

BD Biosciences Cat# 563792, RRID:AB_2869519

Antibody Information

URL: http://antibodyregistry.org/AB_2869519

Proper Citation: BD Biosciences Cat# 563792, RRID:AB_2869519

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Hu CD45 BUV395 HI30 100Tst

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: HI30

Antibody ID: AB_2869519

Vendor: BD Biosciences

Catalog Number: 563792

Record Creation Time: 20250819T233604+0000

Record Last Update: 20250820T055100+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD45 BUV395 HI30 100Tst.

No alerts have been found for Hu CD45 BUV395 HI30 100Tst.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Deng J, et al. (2026) Macrophage MR1 antigen presentation promotes MAIT cell immunity and lung microbiota modulation. *Science (New York, N.Y.)*, 391(6782), eadr6322.

Abrey-Recalde MJ, et al. (2026) Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer. *Cell death & disease*.

Gattinoni L, et al. (2026) Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. *Cell*, 189(12), 3686.

Savage G, et al. (2026) Phenotypic Characterization and Prognostic Impact of CD103+ Tissue-Resident Memory T Cells in Diffuse Large B-cell Lymphoma. *Cancer immunology research*, 14(2), 291.

Fernandes P, et al. (2026) Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice. *Cell host & microbe*, 34(1), 116.

La C, et al. (2026) In vivo modeling of human ?? T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 V?2 T cell development. *Cell reports*, 45(2), 116977.

Chen S, et al. (2026) PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma. *Cancer cell*.

Krapi? M, et al. (2025) NK cell-derived IFN? mobilizes free fatty acids from adipose tissue to promote early B cell activation during viral infection. *Nature metabolism*, 7(5), 985.

Cooney JP, et al. (2025) Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo. *Cell*, 188(18), 4896.

Hasanov M, et al. (2025) Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. *Oncoimmunology*, 14(1), 2546402.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.

Garcia GL, et al. (2025) Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. *Cancer discovery*, 15(6), 1203.

Yang BH, et al. (2025) iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. *Cell reports. Medicine*, 6(7), 102195.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. *Frontiers in immunology*, 16, 1609658.

Gaspar M, et al. (2025) An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. *Journal for immunotherapy of cancer*, 13(8).

Chauveau C, et al. (2025) MEK inhibition prevents human skin graft rejection by promoting CD8+TCF1+ over CD8 effector T cells. *iScience*, 28(9), 113310.

Liu L, et al. (2025) TWEAK-Fn14 signaling protects mice from pulmonary fibrosis by inhibiting fibroblast activation and recruiting pro-regenerative macrophages. *Cell reports*, 44(2), 115220.

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. *Cell*, 187(3), 624.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. *Cell stem cell*, 31(9), 1376.

Li Z, et al. (2024) Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors. *STAR protocols*, 5(3), 103096.